Poly Medicure vs Molbio Diagnostics
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Molbio Diagnostics currently has the stronger revenue growth signal.
Poly Medicure and Molbio Diagnostics show active capex signals based on earnings call analysis.
No strong fundraising signal is currently visible for either company.
| Metric | Poly Medicure | Molbio Diagnostics |
|---|---|---|
| Current Price | ₹1,449.5 | ₹1,274 |
| Market Cap | ₹14,690.5 Cr. | ₹14,681.6 Cr. |
| Industry | Healthcare Equipment & Supplies | Healthcare Equipment & Supplies |
| P/E Ratio | 45.9 | 67.62 |
| ROE (%) | 9.02 | 13.84 |
| Debt/Equity | 0.11 | 0.3 |
| Sales Growth 5Y (%) | 19.01 | 0.65 |
| Profit Growth 5Y (%) | 7.65 | — |
| Promoter Holding (%) | 62.42 | 41.29 |
| Revenue Rank | Rank 3 | Rank 2 |
| Margin Rank | Rank 3 | Rank 3 |
| Signal | — | — |
| Capex | Yes | Yes |
| Fundraise | No information | No information |
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.